Synthesis, cytotoxicity and mechanistic evaluation of 4-oxoquinoline-3- carboxamide derivatives: Finding new potential anticancer drugs

Molecules

Volumn 19, Issue 5, 2014, Pages 6651-6670

  Forezi, Luana Da S M ^a   Tolentino, Nathalia M C ^a   De Souza, Alessandra M T ^b   Castro, Helena C ^a   Montenegro, Raquel C ^c   Dantas, Rafael F ^d   Oliveira, Maria E I M ^d   Silva Jr , Floriano P ^d   Barreto, Leilane H ^c   Burbano, Rommel M R ^c   Abrahim Vieira, Bárbara ^b   De Oliveira, Riethe ^b   Ferreira, Vitor F ^a   Cunha, Anna C ^a   Boechat, Fernanda Da C S ^a   De Souza, Maria Cecília B V ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

4 oxoquinoline; Anticancer; Carboxamide; Heterocycles

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HEMOLYTIC AGENT; QUINOLONE DERIVATIVE;

ANIMAL; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; DRUG SCREENING; ERYTHROCYTE; HUMAN; IC50; MOLECULAR DOCKING; MOUSE; STOMACH NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; CHEMISTRY TECHNIQUES, SYNTHETIC; COMPUTER SIMULATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ERYTHROCYTES; HEMOLYTIC AGENTS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; QUINOLONES; STOMACH NEOPLASMS;

EID: 84901413160     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19056651     Document Type: Article

References (34)

1. Suthar S.K.; Jaiswal W.; Lohan S.; Bansal S.; Chaudhary A.; Tiwari A.; Alex A.T.; Joesph A. Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. Eur. J. Med. Chem. 2013, 63, 589-602.
2. Mitscher L.A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents. Chem. Rev. 2005, 105, 559-592.
3. Ahmed A.; Daneshtalab M. Nonclassical Biological Activities of Quinolone Derivatives. J. Pharm. Pharm. Sci. 2012, 15, 52-72.
4. Mugnaini C.; Pasquini S.; Corelli F. The 4-quinolone-3-carboxylic acid motif as a multivalent Scaffold in Medicinal Chemistry. Curr. Med. Chem. 2009, 16, 1746-1767.
5. Audisio D.; Messaoudi S.; Peyrat J.F.; Brion J.D.; Alami M.J. A general copper powder-catalyzed ullmann-Type reaction of 3-halo-4(1H)-quinolones with variousnitrogen-containingnucleophiles. J. Org. Chem. 2011, 76, 4995-5005.
6. Xia Y.; Yang Z.; Xia P.; Hackl T.; Hamel E.; Mauger A.; Wu J.; Lee K. Antitumor agents. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J. Med. Chem. 2001, 44, 3932-3936.
7. Abbas J.A.; Stuart R.K. Vosaroxin: A novel antineoplasic quinolone. Expert Opin. Investig. Drugs 2012, 21, 1223-1233.
8. Advani R.H.; Hurwitz H.I.; Gordon M.S.; Ebbinghaus S.W.; Mendelson D.S.; Wakelee H.A. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: A report on two dosing schedules. Clin. Cancer Res. 2010, 16, 2167-2175.
9. Lai Y.; Huang L.; Lee K.; Xiao Z.; Bastow K.F.; Yamiri T.; Kuo S. Synthesis and biological relationships of 3', 6-substituted 2-phenyl-4- quinolone-3-carboxylic acid derivatives as antimitotic agents. Bioorg. Med. Chem. 2005, 13, 265-275.
10. Rajabalian S.; Foroumadi A.; Shafiee A.; Emami A. Functionalized N-(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents. J. Pharm. Pharm. Sci. 2007, 10, 153-158.
11. Abe H.; Kawada M.; Inoue H.; Ohba S.; Nomoto A.; Watanabe T.; Shibasaki M. Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents. Org. Lett. 2013, 15, 2124-2127.
12. Hawtin R.E.; Stockett D.E.; Byl J.A.W.; Mcdowell R.S.; Tan N.; Arkin M.R. Structural biology of human H3K9 methyltransferases. PLoS One 2010, 5, e8570.
13. Foroumadi A.; Emami S.; Rajabalian S.; Badinloo M.; Mohammdhosseini N.; Shafiee A. N-Substituted piperazinyl quinolones as potential cytotoxic agents: Structure-Activity relationships study. Biomed. Pharmacother. 2009, 63, 216-220.
14. Chen Y.; Chung C.; Chen I.; Chen P.; Jeng H. Synthesis and cytotoxic activity evaluation of indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-Anilinoindoloquinoline derivatives. Bioorg. Med. Chem. 2002, 10, 2705-2712.
15. Sabbah D.; Simms N.; Wang W.; Dong Y.; Ezell E.L.; Brattain M.G.; Vennerstrom J.L.; Zhong H.A. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα). Bioorg. Med. Chem. 2012, 20, 7175-7183.
16. Voreloxin is not in the market (but in clinical trial) and literature still ask about its ability of replacing the anthracycline drugs, requesting future investigation to confirm its efficacy. Altogether these data point doxorubicin as the best control drug to compare our active experimental profile against cancer cell lines, see: Freeman C.; Keane N.; Swords R.; Giles F. Vosaroxin: A new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin. Pharmacother. 2013, 14, 1417-1427.
17. Gould R.G.; Jacobs W.A. The Synthesis of Certain Substituted Quinolines and 5, 6-Benzoquinolines. J. Am. Chem. Soc. 1939, 61, 2890-2895.
18. Snyder H.R.; Freier H.E.; Kovacic P.; Heyningen E.M.V. Synthesis of 4-hydroxyquinolines. VIII. Some halogen containing 4-Aminoquinoline derivatives. J. Am. Chem. Soc. 1947, 69, 371-373.
19. Stern E.; Muccioli G.G.; Millet R.; Goossens J.-F.; Farce A.; Chavatte P.; Poupaert J.H.; Lambert D.M.; Depreux P.; Hénichart J.-P. Novel 4-oxo-1, 4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: Synthesis, pharmacological properties, and molecular modeling. J. Med. Chem. 2006, 49, 70-79.
20. Riegel B.; Lappin G.R.; Adelson B.H.; Jackson R.I.; Albisetti C.J., Jr.; Dodson R.M.; Baker R.H. The synthesis of some 4-quinolinols and 4-chloroquinolines by the ethoxymethylenemalonic ester method. J. Am. Chem. Soc. 1946, 68, 1264-1266.
21. Matta A.D.; Bernardino A.M.R.; Romeiro G.A.; Oliveira M.R.P.; Souza M.C.B.V.; Ferreira V.F. Nucleosides having quinolone derivatives as nitrogenated base: Regiospecific and stereospecific ribosylation of 3-carbethoxy-1, 4-dihydro-4-oxoquinolines. Nucleos. Nucleot. Nucleic Acids 1996, 15, 889-898.
22. Doxorubicin is one of the most important anticancer chemotherapeutic drug currently in use. Importantly, despite of its side effects, it is still in use and new formulations options are still being investigated due to its significant therapeutic profile, see: Deepa K.; Singha S.; Panda T.J. doxorubicin nanoconjugates. Nanosci. Nanotechnol. 2014, 14, 892-904.
23. Wu C.C.; Li T.K.; Farh L.; Lin L.Y.; Lin T.S.; Yu Y.J.; Yen T.J.; Chiang C.W.; Chan N.L. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 2011, 333, 459-462.
24. Esteves-Souza A.; Rodrigues-Santos C.E.; del Cistia C.N.; Silva D.R.; Sant'anna C.M.R.; Echevarria A. Solvent-free synthesis, DNA-Topoisomerase II activity and molecular docking study of new asymmetrically N, N'-substituted ureas. Molecules 2012, 17, 12882-12894.
25. Lipinski C.A. Lead-And drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004, 4, 337-341.
26. Gajbhiye A.; Chaturvedi L. Synthesis of 4-quinolones derivatives for their antihistaminic activity. Int. J. Pharm. Pharm. Sci. 2013, 5, 223-227.
27. Shah K.J.; Coats E.A. Design, synthesis, and correlation analysis of 7-Substituted4-hydroxyquinoline-3-carboxylic acids as inhibitors of cellular respiration. J. Med. Chem. 1977, 20, 1001-1006.
28. Wathen L.K.; Wathen L.M. Method of Preventing or Treating Atherosclerosis or Restenosis. U.S. Patent WO2004019932 (A1), 11 March 2004.
29. Sheth U.; Fanning T.T.D.; Numa M.; Binch H.; Hurley D.J.; Zhou J.; Hadida R.S.S.; Hazlewood A.R.; Silina A.; Vairagoundar R.; et al. 4-Oxo-1H-Quinoline- 3-Carboxamides as Modulators of ATP-Binding Cassette Transporters. U.S. Patent WO2011072241 (A9), 16 June 2011.
30. Singh A.; van Goor F.; Worley L.J.F.; Jennings F.; Knapp T. Compounds Useful in Cftr Assays and Methods Therewith. U.S. Patent WO 2007075946 (A1), 5 July 2007.
31. Verdonk M.L.; Berdini V.; Hartshorn M.L.; Mooij W.T.; Murray C.W.; Taylor R.D.; Watson P. Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 2004, 44, 793-806.
32. Verdonk M.L.; Cole J.C.; Hartshorn M.J.; Murray C.W.; Taylor R.D. Improved protein-ligand docking using GOLD. Proteins: Struct. Funct. Genet. 2003, 52, 609-623.
33. Sander T. Actelion Pharmaceuticals Ltd. Available online: http://www.organic-chemistry.org/(accessed on 13 May 2014).
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.